Drug Trial Radar · NCT00707941
Oseltamivir Randomised Controlled Efficacy Trial
Last checked: Nov 20, 2026Latest source record: Jun 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,190
Actual
Start
May 2008
Primary completion
Mar 2011
Study completion Mar 2011
Sponsor
- Lead sponsor
- International Centre for Diarrhoeal Disease Research, BangladeshAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Centers for Disease Control and Prevention
- First posted
- Jul 1, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background In preparation for a global influenza pandemic, there is an urgent need for representative data from populations and settings where the pandemic is most likely to arise. There are no data on oseltamivir efficacy from Asian urban slum populations concerning duration of illness and viral shedding, nor whether efficacy depends on starting treatment \< 48 hours or ≥ 48 hours after illness onset. Finally, there are no data on the capacity of the drug, in such settings, to affect household and community transmission rates. Aims and Objectives This proposal aims to compare the duration of clinical illness among patients treated with oseltamivir vs placebo \< 48 hours and ≥ 48 hours after illness onset. It will compare the duration of viral shedding among all treatment groups vs placebo, risk of transmission to household contacts by treatment group and whether neuraminidase inhibitor use creates resistance. Secondarily it aims to measure the effect on influenza. Design and Methods A double-blind placebo controlled clinical trial design among a population in an urban slum under current influenza disease burden surveillance will be enrolled. Infection status will be confirmed by rRT-PCR. Patients ≥ 1 year old will be randomised to \< 48 hour and ≥ 48 hour treatment arms. Family members and neighbours will also be assessed by PCR and a basic reproductive number calculated (R0). Relevance These findings will address whether oseltamivir can affect illness duration and severity, affect transmission, incidence and resistance in high risk urban Asian settings where a pandemic is most likely to arise.
Conditions
- Influenza
- Pneumonia
- Lower Respiratory Tract Infection
- Upper Respiratory Tract Infection
- Viral Shedding
Interventions
OseltamivirDrug
Children ≤12 years: Suspension by Weight (Kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml) Patients≥12 years: 75 mg capsules as follows: 1 cap (75 mg) PO BID X 5 days ≥ 40 75 mg PO BID 6.25
PlaceboDrug
Children \< 12 years, suspension by weight (kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml) Patients≥12 years: 75 mg capsules as follows 1 cap (75 mg) PO BID X 5 days ≥ 40 75 mg PO BID 6.25
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of clinical illness among patients treated with oseltamivir vs placebo < 48 hours as well as ≥48 hours after illness onsetTime frame: 18 months
- Duration of viral shedding among all treatment groups vs placeboTime frame: 18 months
- Compare the risk of transmission to household contacts by treatment group vs placeboTime frame: 18 months
- The effect of neuraminidase inhibitor use on the emergence of resistanceTime frame: 18 months
- Clinical complications associated with influenza among all treatment groups vs placeboTime frame: 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kamalapur Urban Site, ICDDR,B
Dhaka, Bangladesh
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.